---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-25-000800"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:47:44.890599+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TOI Q1 revenue $104.4M (+10.3% YoY); net loss $19.6M vs $19.9M; reaffirms FY2025 guidance

## Summary
- Revenue $104.4M, up 10.3% YoY from $94.7M; gross profit $17.2M, up 44.1%.
- Net loss $19.6M ($0.21/share) vs $19.9M ($0.22) prior year; Adjusted EBITDA -$5.1M vs -$10.9M.
- Pharmacy & Dispensary segment revenue $49.3M, gross profit >$9M, grew >20% YoY; FFS growth 9% QoQ.
- Added >100,000 capitated lives in Q1; new contracts in FL, NV, CA; fully-delegated agreement started March 1 in FL.
- Closed $16.5M private placement; exchanged $4.1M convertible notes for preferred stock & warrants; cash $39.7M.

## SEC filing metadata
- accession: 0001079973-25-000800
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000107997325000800/0001079973-25-000800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000107997325000800/toi_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-25-000800
- JSON: https://secwatch.observer/filing/0001079973-25-000800.json
- Plain text: https://secwatch.observer/filing/0001079973-25-000800.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.